0000000000383252

AUTHOR

R. Sciacchitano

showing 6 related works from this author

502P Impact of different selection approaches for identifying Lynch syndrome-related colorectal cancer patients

2021

Oncologymedicine.medical_specialtyOncologybusiness.industryColorectal cancerInternal medicineMedicineHematologybusinessmedicine.diseaseSelection (genetic algorithm)Lynch syndromeAnnals of Oncology
researchProduct

POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes

2021

POLE, POLD1, and NTHL1 are involved in DNA replication and have recently been recognized as hereditary cancer-predisposing genes, because their alterations are associated with colorectal cancer and other tumors. POLE/POLD1-associated syndrome shows an autosomal dominant inheritance, whereas NTHL1-associated syndrome follows an autosomal recessive pattern. Although the prevalence of germline monoallelic POLE/POLD1 and biallelic NTHL1 pathogenic variants is low, they determine different phenotypes with a broad tumor spectrum overlapping that of other hereditary conditions like Lynch Syndrome or Familial Adenomatous Polyposis. Endometrial and breast cancers, and probably ovarian and brain tumo…

MaleCancer ResearchSettore MED/06 - Oncologia MedicaColorectal cancerBiologymedicine.disease_causeGermlineFamilial adenomatous polyposisDeoxyribonuclease (Pyrimidine Dimer)Breast cancerNeoplasmsGeneticsmedicineHumansGenetic Predisposition to DiseasePoly-ADP-Ribose Binding ProteinsMolecular BiologyDNA Polymerase IIIGenetic testingMutationPOLD1medicine.diagnostic_testDNA Polymerase IIDNAmedicine.diseaseLynch syndromePOLE POLD1 and NTHL1Lynch SyndromeCancer researchFemaleOncogene
researchProduct

162P Prevalence and spectrum analysis of germline BRCA1 and BRCA2 variants of unclear significance in HBOC Syndrome: Decoding the mysterious signals …

2021

GeneticsOncologybusiness.industryHBOC SyndromeMedicineHematologySpectrum analysisbusinessGenomeGermlineDecoding methodsAnnals of Oncology
researchProduct

166P Hereditary breast, ovarian and pancreatic cancers: Looking beyond the BRCA1/2 genes

2021

Oncologybusiness.industryCancer researchMedicineHematologybusinessGeneAnnals of Oncology
researchProduct

167P Role of the multi-gene panel testing for detection of pathogenic variants in patients with hereditary bilateral breast cancer

2021

Oncologymedicine.medical_specialtyOncologybusiness.industryInternal medicineMedicineIn patientHematologybusinessBilateral breast cancerMulti geneAnnals of Oncology
researchProduct

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

2021

About 10–20% of breast/ovarian (BC/OC) cancer patients undergoing germline BRCA1/2 genetic testing have been shown to harbor Variants of Uncertain Significance (VUSs). Since little is known about the prevalence of germline BRCA1/2 VUS in Southern Italy, our study aimed at describing the spectrum of these variants detected in BC/OC patients in order to improve the identification of potentially high-risk BRCA variants helpful in patient clinical management. Eight hundred and seventy-four BC or OC patients, enrolled from October 2016 to December 2020 at the “Sicilian Regional Center for the Prevention, Diagnosis and Treatment of Rare and Heredo-Familial Tumors” of University Hospital Policlini…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyendocrine system diseasesGenomeGermlinegenetic testing03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerInternal medicinemedicineClinical significanceskin and connective tissue diseasesRC254-282Original ResearchGenetic testingAnamnesismedicine.diagnostic_testbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerBRCA1medicine.diseaseBRCA2ovarian cancer030104 developmental biologyOncology030220 oncology & carcinogenesisvariants of uncertain significance (VUS)Ovarian cancerbusinessFrontiers in Oncology
researchProduct